Lexicon's Sotagliflozin Shows Benefits in Heart Failure, Blood Glucose Control

by Vandana Singh, Benzinga Editor

November 15, 2021 3:02 PM | 1 min read

Lexicon Pharmaceuticals Inc LXRX has announced a new analysis evaluating the benefit of sotagliflozin in heart failure and blood glucose control across the full range of kidney function.
In the new analysis of pooled data from the SOLOIST and SCORED trials, sotagliflozin consistently reduced total cardiovascular deaths, hospitalizations for heart failure, and urgent visits for heart failure.
Sotagliflozin also significantly reduced hemoglobin A1c.
The pooled analysis of clinical data from the SOLOIST and SCORED trials involved a total of 11,806 patients with diabetes and heart failure or cardiovascular risk factors.
Price Action: LXRX shares are up 1.67% at $5.19 during the market session on Monday's last check.

Posted In: Biotech News Health Care Small Cap General Biotechnology Briefs Health Care

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.